
iBio fell 23.8% from $1.05 to $0.80, behind the S&P 500's +4.7%. Its worst day was Mar 26 (−20.2%), and its low came Nov 16 at $0.71.
Nov 21, 2025 – Nov 20, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
iBio shares rose 39.2%, while the S&P 500 fell 0.3%.
+39.2%, the year's best day, on 114M shares, the year's heaviest volume · S&P 500 −0.3%
EPS of $-0.09 missed the $-0.07 estimate on $0.00 revenue (est. $59,998.00).
Story events cover the past 12 months · Times ET
−2.6% · S&P 500 0.0%
iBio closed at its highest level of the year, 192.4% above where the year started.
+7.0% · S&P 500 −0.6%
iBio shares fell 20.2%, while the S&P 500 fell 1.8%.
−20.2%, the year's worst day · S&P 500 −1.8%
EPS of $-0.07 missed the $-0.06 estimate on $0.00 revenue (est. $36,000.00).
−3.7% · S&P 500 +0.6%
EPS of $-0.06 beat the $-0.06 estimate on $0.00 revenue (est. $66,670.00).
−2.9% · S&P 500 −0.2%
EPS of $-0.05 beat the $-0.07 estimate on $1.1M revenue (est. $16,670.00).
+5.7% · S&P 500 +1.3%
Where it ended: a close of $0.80 on Nov 20, 2026. Up next: Q2 2027 earnings on Feb 9, 2027 (EPS est. $-0.07, revenue est. $16,670.00).
Nothing in the past 12 months.
All IBIO dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for IBIO and SPY from Benzinga historical bars. Not investment advice.